Infliximab biosimilar - Celltrion

Drug Profile

Infliximab biosimilar - Celltrion

Alternative Names: Anti-TNF alpha Mab; Anti-TNF alpha monoclonal antibody; CT-P13; Inflectra; Infliximab biosimilar - Hospira; Infliximab BS; infliximab-dyyb; Remsima

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltrion
  • Developer Alvogen; Celltrion; Hospira; Nippon Kayaku; Orion
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 21 Feb 2018 Phase-I clinical trials in Ulcerative colitis (In volunteers) in USA (SC)
  • 28 Oct 2017 Safety and pharmacokinetics data from a phase I trial in Crohn's disease and Ulcerative colitis presented at the 25th United European Gastroenterology Week (UEG-2017)
  • 17 Aug 2017 Launched for Ankylosing spondylitis in Thailand (IV) (TCTR20170817005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top